Biopharmaceutical improvement of praziquantel by interaction with montmorillonite and sepiolite
Source abstract
Abstract
Abstract Praziquantel is the drug of first choice for the treatment of the human schistosomiasis. It is administered orally, requiring high doses to overcome adverse biopharmaceutical properties, including high lipophilia and intense hepatic first pass metabolism. According to its biopharmaceutical profile, praziquantel has very low water solubility and high permeability. Therefore, dissolution is the limiting factor for absorption in the gastrointestinal tract. Improvement of the aqueous solubility of the drug would reduce the currently high oral doses. Meanwhile, montmorillonite and sepiolite are clay minerals, with a high adsorption and swelling properties, potentially useful as a low-cost nanocarrier to design praziquantel delivery systems. In this work, the interactions between the drug and clay minerals are studied experimentally, with the aim of improving the biopharmaceutical profile of the drug. The results showed the effective loading of the drug in the clay minerals as well as the significant increase of the dissolution rate and the dissolved amount of praziquantel, potentially improving the bioavailability of the drug.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Therapeutic Uses of Natural Elements · Clay minerals and soil interactions · Alkaline Phosphatase Research Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (34)
Show source-provided references
1. Influence of dispersion conditions of two pharmaceutical grade clays on their interaction with some tetracyclines10.1016/j.clay.2005.03.007 ↗
2. Use of clays as drug delivery systems: possibilities and limitations
3. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability10.1023/A:1016212804288 ↗
4. Praziquantel: mechanisms of anti-schistosomal activity10.1016/0163-7258(85)90020-8 ↗
5. Chapter 1 general introduction: clays, clay minerals, and clay science10.1016/S1572-4352(05)01001-9 ↗
6. Molecular and crystal structure of praziquantel. Spectroscopic properties and crystal polymorphism10.1016/j.ejps.2016.04.023 ↗
7. Molecular modeling and infrared and Raman spectroscopy of the crystal structure of the chiral antiparasitic drug praziquantel
8. Polyethylene glycol/clay nanotubes composites. Thermal properties and structure10.1007/s10973-012-2766-8 ↗
9. Solid dispersions with hydrogenated castor oil increase solubility, dissolution rate and intestinal absorption of praziquantel10.1590/S1984-82502010000300010 ↗
10. Development and evaluation of praziquantel solid dispersions in sodium starch glycolate
11. The global status of schistosomiasis and its control10.1016/S0001-706X(00)00122-4 ↗
12. Preparation, dissolution and characterization of Praziquantel solid dispersions10.1248/cpb.47.1629 ↗
13. Praziquantel in a clay nanoformulation shows more bioavailability and higher efficacy against murine Schistosoma mansoni infection10.1128/AAC.04875-14 ↗
14. Praziquantel10.1016/S0099-5428(08)60760-1 ↗
15. Cocrystals of active pharmaceuticals ingredients-praziquantel in combination with oxalic, malonic, succinic, maleic, fumaric, glutaric, adipic and pimelic acids10.1021/cg301314w ↗
16. FDA
17. Near-infrared and mid-infrared spectroscopic study of sepiolites and palygorskites10.1016/S0924-2031(01)00110-2 ↗
18. In vitro characterization of some biopharmaceutical properties of praziquantel10.1016/j.ijpharm.2005.01.033 ↗
19. Summary of recommendations of nomenclature committees relevant to clay mineralogy: report of the association internationale pour l'etude des argiles (aipea) nomenclature committee for 200610.1346/CCMN.2006.0540610 ↗
20. Structural characterization and enantioseparation of the chiral compound praziquantel10.1002/jps.20211 ↗
21. Pharmaceutical and cosmetic applications of clays10.1016/S1573-4285(04)80044-9 ↗
22. Effect of morphology and size of halloysite nanotubes on functional pectin bionanocomposites for food packaging applications10.1021/acsami.7b04297 ↗
23. Martín-Ramos, J.D., 2005. XPowder software. http://www.xpowder.com.X-Power.
24. Direct chemical grafted curcumin on halloysite nanotubes as dual-responsive prodrug for pharmacological applications10.1016/j.colsurfb.2016.01.025 ↗
25. Crystal structure and hydroxyl group vibrational frequencies of phyllosilicates by DFT methods10.1016/j.theochem.2009.02.013 ↗
26. Evaluation of melt granulation and ultrasonic spray congealing as techniques to enhance the dissolution of praziquantel10.1016/j.ijpharm.2006.03.028 ↗
27. Computational analysis and physico-chemical characterization of an inclusion compound between praziquantel and methyl-β-cyclodextrin for use as an alternative in the treatment of schistosomiasis10.1007/s10847-010-9852-y ↗
28. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk10.1016/S1473-3099(06)70521-7 ↗
29. Variability of the surface properties of sepiolite10.1016/j.clay.2012.06.003 ↗
30. Geochemistry of Spanish sepiolite-palygorskite deposits: genetic considerations based on trace elements and isotopes10.1016/0009-2541(94)90026-4 ↗
31. Pharmaceutical applications of some spanish clays (sepiolite, palygorskite, bentonite): some preformulation studies10.1016/S0169-1317(98)00050-7 ↗
32. Current challenges in clay minerals for drug delivery10.1016/j.clay.2010.01.007 ↗
33. Susceptibility or resistance of praziquantel in human schistosomiasis: a review10.1007/s00436-012-3151-z ↗
34. WHO